Shots:

• The approval is based on REFLECTIONS B3281006 study results assessing Ruxience vs reference product- Rituxan (rituximab) in patients with CD20-positive- low tumor burden follicular lymphoma
• The REFLECTIONS B3281006 study results demonstrated biosimilarity data of Ruxience to the reference product. Ruxience is the third biosimilar of Pfizer’s oncology portfolio to be approved in the US in 2019
• Ruxience (rituximab-pvvr) is an anti-CD20 mAb which acts by targeting CD20 present on the surface of B-cells- approved for NHL- CLL- GPA and MPA in the US and is under EMA’s review in Europe

Click here to read full press release/ article | Ref: Pfizer | Image: Pinterest